October 2023 - Page 4 of 4 - BioMedWire (BMW)

ThursdayOct 05, 2023 12:38 pm

Researchers Find Psoriasis Increases Risk of Heart Disease

Researchers have observed coronary microvascular dysfunction in a good number of patients with psoriasis. This is despite the fact that most of them hadn’t presented with any symptoms of cardiovascular illness. For their study, the researchers recruited 503 individuals who had been diagnosed with psoriasis but had not been diagnosed with cardiovascular disease. Prior research has demonstrated that individuals with severe psoriasis have heightened cardiovascular mortality and morbidity. Despite this, there’s been limited studies on the mechanisms underlying the heightened risk. The researchers were focused on learning more about the link between psoriasis and heart disease, centering on coronary blood…

WednesdayOct 04, 2023 3:32 pm

New Prediction Model Could Slash Unnecessary Pancreatic Cancer Biopsies

Researchers have developed a new prediction model capable of “reliably detecting” pancreatic cancer in its early stages. The prediction model leverages regularly measured biomarkers in the blood to sharpen diagnostic processes for pancreatic cancer and reduce the need for unnecessary biopsy procedures by 6%. Pancreatic cancer is difficult to diagnose in its early stages because the pancreas is generally hidden by other organs and is located deep in the abdomen. Furthermore, pancreatic cancer often displays no physical symptoms until the cancer has metastasized to other organs, which makes the condition easy to miss during physical exams or through analyzing symptoms.…

WednesdayOct 04, 2023 9:45 am

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Secures $1.33 Million from Registered Direct Offering to Boost Commercial Development

Scinai Immunotherapeutics recently announced the closing of a registered direct offering, raising $1.33 million in gross proceeds The company intends to use the net proceed from the offering for, among others, research and development On its R&D agenda is the development and commercialization of novel innovative NanoAbs targeting a wide range of diseases with known and validated antibody drug targets This strategic approach is expected to shorten development timelines, reduce the budgetary requirements, and increase probability of drug approval The company has also expanded into the CDMO business to plug an existing gap in the market, raising recurring revenue as…

TuesdayOct 03, 2023 1:51 pm

TikTok Hit as Indonesia Announces e-Commerce Transaction Ban on Social Media

Indonesian authorities dealt a major blow to TikTok’s expansion plans after they announced a national ban on virtual transactions on social media platforms. The social media platform TikTok has been working to accelerate e-commerce transactions in Indonesia, its largest market in Southeast Asia, as it fields increased scrutiny in other markets. However, the country’s government seems to have pulled the rug out from under TikTok’s feet. According to the government, the ban on social media e-commerce transactions is meant to protect offline marketplaces and merchants from the predatory pricing models on social media platforms that often outprice and threaten small…

MondayOct 02, 2023 11:42 am

Novel Type of Immunotherapy Exhibits Efficacy Against Brain Tumors in Mouse Models

A multi-institutional team of researchers has developed a novel type of cellular immunotherapy that has proven its therapeutic effectiveness in mouse models. Comprised of a researcher from the German Cancer Research Center and a University Medical Center Mannheim physician, the team used NLGN4X-specific T cells to successfully kill brain tumor cells from mice. NLGN4X (Neuroligin4X) is a protein that is involved in protein formation, and it occurs in large amounts in glioblastoma tumor cells even though they are barely present in healthy brain tissue. Glioblastoma is a type of brain cancer that originates in the nerve cell astrocytes within the…

MondayOct 02, 2023 9:00 am

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Finalizes Rebrand to Reflect New Strategic Direction, Diversification

Scinai Immunotherapeutics, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, recently finalized a major rebrand, changing its corporate name from BiondVax Pharmaceuticals The rebrand is part of a series of steps to better reflect the company’s new direction and new developments aimed at new scientific breakthroughs Amir Reichman took over as CEO in March 2021 and together with the Board of Directors, began implementing a raft of changes aimed at redirecting the company’s focus and diversifying corporate risks Scinai is developing a pipeline of novel NanoAbs, with its development pipeline including NanoAbs for the treatment of…